This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Tuesday's Health Winners & Losers

Updated from 11:43 a.m. EDT

Positive earnings news out of Johnson & Johnson (JNJ - Get Report) was leading the headlines on the Dow Jones Industrial Average and among health care stocks Tuesday.

Johnson & Johnson said first-quarter earnings fell to $2.6 billion, or 88 cents a share, from $3.3 billion, or $1.10 a share, a year ago. However, adjusted results topped the Thomson First Call analysts' consensus of $1.05 a share, and J&J was higher by $1.53, or 2.4%, at $64.55.

Other pharmaceutical stocks lost ground. Wyeth (WYE) was off 0.8%, Merck (MRK) was down 0.6%, and Pfizer (PFE) dipped 0.2%.

J&J's gain helped boost the Amex Pharmaceutical Index, which was up slightly. The Amex Biotechnology Index also gained ground, despite losses of 0.7% or more in Cephalon (CEPH), Human Genome Sciences (HGSI), and MedImmune (MEDI).

Elsewhere, Novacea (NOVC) surged after the company said its AQ4N compound looked to be effective during animal studies. The treatment targets oxygen-starved regions of cancerous tumors that are hard to reach with other cancer therapies. The stock jumped $1.32, or 19.7%, to $8.02.

Shares of Telik (TELK) also soared after the company reported positive Phase II clinical data for its lung cancer drug candidate Telcyta. After rising more than 20% earlier in the day, Telik closed up 54 cents, or 9.2%, at $6.43.

On the flip side, biotech company Antigenics (AGEN - Get Report) shed 10.6% a day after the company said its Oncophage cancer vaccine showed positive results in a clinical trial as a treatment for brain cancer. Antigenics, which surged 20.7% on Monday, lost 47 cents to $3.96.

BioMarin Pharmaceutical (BMRN - Get Report) also sank a day after the company offered $250 million in senior subordinated convertible bonds, with an underwriter's option for $37.5 million more to cover overallotments. BioMarin fell $1.21, or 6.8%, to $16.62.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
NOVC $0.07 2.86%
AGEN $3.25 -7.10%
BMRN $82.31 -3.30%
JNJ $112.32 -0.33%
TELK $2.75 -8.33%


Chart of I:DJI
DOW 17,668.69 -82.22 -0.46%
S&P 500 2,051.97 -11.40 -0.55%
NASDAQ 4,728.9080 -34.3160 -0.72%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs